Over the past ten years, more and more pharma and biotech companies have turned to CROs, CMOs and CDMOs to assist in the preformulation, development and manufacturing of their latest innovations. Outsourcing is now a multi-billion dollar industry. Most spending is focused on early development, with around two-thirds of annual spending being outsourced. This report, commissioned by Biopharma Group, discusses why so many pharma and biotech companies have transitioned from doing their R&D in-house to outsourcing it.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/12/The-era-of-pharma-and-biotech.pdf” width=”100%” height=”900px” style=”border:0;”]